Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × Letrozole × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 100 Endometrial Neoplasms 15 Neoplasm Metastasis 8 Polycystic Ovary Syndrome 7 Ovarian Neoplasms 7 Neoplasms 7 Fallopian Tube Neoplasms 4 Recurrence 3 Prostatic Neoplasms 3 Infertility 3 Carcinoma, Intraductal, Noninfiltrating 3 Advanced Breast Cancer 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Progesterone Resistance 2 Neoplasms by Site 2 Hereditary Sensory and Autonomic Neuropathies 2 Head and Neck Neoplasms 2 Endometrial Hyperplasia 2 Breast Neoplasms, Male 2 Breast Diseases 2 Breast Cancer Metastatic 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Obesity 1 Neoplastic Cells, Circulating 1

Interventions

Letrozole 1 Fulvestrant 1 Epirubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡